We are live on ! Find out more
PBPIA

Pivotal bioVenture Partners Investment Advisor Portfolio holdings

AUM $280M
1-Year Est. Return 181.4%
This Fund
S&P 500
This Quarter Est. Return
+32.31%
1 Year Est. Return
+181.4%
3 Year Est. Return
+730.97%
5 Year Est. Return
+1,157.4%
10 Year Est. Return
–
AUM
$259M
AUM Growth
+$85.7M
Cap. Flow
+$24.8M
Cap. Flow %
9.58%
Top 10 Hldgs %
99.16%
Holding
12
New
2
Increased
1
Reduced
3
Closed
–

Top Buys

Rank Stock Value
1
EVMN
Evommune Inc
EVMN
+$36.2M
2
MPLT
MapLight Therapeutics
MPLT
+$10.2M
3
IMNM icon
Immunome
IMNM
+$4.04M

Top Sells

Rank Stock Value
1
ARQT icon
Arcutis Biotherapeutics
ARQT
+$19.3M
2
ZBIO
Zenas BioPharma
ZBIO
+$6.15M
3
OCS icon
Oculis Holding
OCS
+$242K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCVX icon
1
Vaxcyte
PCVX
$8.93B
$63.3M 24.48%
1,372,425
– –
OCS icon
2
Oculis Holding
OCS
$715M
$45.7M 17.67%
2,288,658
-12,116
-0.5% -$242K
ARQT icon
3
Arcutis Biotherapeutics
ARQT
$3.28B
$39.7M 15.34%
1,366,624
-753,884
-36% -$19.3M
EVMN
4
Evommune Inc
EVMN
$510M
$33M 12.75%
+1,926,943
New +$36.2M
ZBIO
5
Zenas BioPharma
ZBIO
$1.99B
$21.5M 8.31%
591,991
-187,054
-24% -$6.15M
TRVI icon
6
Trevi Therapeutics
TRVI
$2.57B
$15.7M 6.08%
1,256,782
– –
IMNM icon
7
Immunome
IMNM
$3.09B
$15.7M 6.08%
732,512
+230,000
+46% +$4.04M
MPLT
8
MapLight Therapeutics
MPLT
$542M
$10.7M 4.15%
+611,447
New +$10.2M
BIOA
9
BioAge Labs
BIOA
$490M
$8.64M 3.34%
653,374
– –
RXRX icon
10
Recursion Pharmaceuticals
RXRX
$1.77B
$2.44M 0.94%
595,518
– –
RLYB icon
11
Rallybio
RLYB
$86.7M
$1.65M 0.64%
300,581
– –
BOLT icon
12
Bolt Biotherapeutics
BOLT
$6.61M
$517K 0.2%
94,573
– –

Similar funds

HCM
Hall Capital Management Barrington, Rhode Island $280M AUM 14.82% 1-Year Est. Return
OFCM
One Fin Capital Management San Francisco, California $280M AUM 49.87% 1-Year Est. Return
NCM
NCM Capital Management Ramsey, New Jersey $279M AUM 26.47% 1-Year Est. Return
CCC
Compass Capital Corp Braintree, Massachusetts $279M AUM 28.36% 1-Year Est. Return
PHC
Panoramic Hills Capital Road Town $280M AUM
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
SL
SOF Ltd George Town, Cayman Islands $279M AUM 6.12% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $279M AUM 45.74% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor's Q4 2025 Portfolio in Review

As of Q4 2025, Pivotal bioVenture Partners Investment Advisor held 12 positions worth $259M, up 50% from $173M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Pivotal bioVenture Partners Investment Advisor deployed $24.8M of net new capital in Q4 2025, opening 2 new positions and adding to 1 existing holding. Its largest new stake was Evommune Inc: 1,926,943 shares worth $33M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Arcutis Biotherapeutics, an estimated $19.3M trimmed.

  • Pivotal bioVenture Partners Investment Advisor's largest Q4 2025 buy was Evommune Inc: 1,926,943 shares worth $33M.
  • Pivotal bioVenture Partners Investment Advisor added most to Immunome in Q4 2025, an estimated $4.04M increase.
  • Pivotal bioVenture Partners Investment Advisor's biggest Q4 2025 reduction was Arcutis Biotherapeutics, cutting an estimated $19.3M.
  • Pivotal bioVenture Partners Investment Advisor's ten largest holdings make up 99% of its $259M portfolio in Q4 2025.
  • Pivotal bioVenture Partners Investment Advisor opened 2 new positions and closed 0 in Q4 2025.
  • Pivotal bioVenture Partners Investment Advisor's portfolio value rose 50% quarter-over-quarter to $259M.

Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q4 2025, filed 13 Feb 2026.